Dr. Denham is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7400 Crestway Rd
San Antonio, TX 78239Phone+1 210-569-9800Fax+1 210-646-5606
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Family Medicine, 1989 - 1992
Texas College of Osteopathic MedicineClass of 1989
William & MaryNo Degree, Radiation Biology, 1981 - 1983- Hampden-Sydney CollegeB.S., Biology, 1977 - 1981
Certifications & Licensure
TX State License 1990 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification athenaClinicals EHR, athenahealth, Inc, 2013
- Phi Gamma Delta Hampden-Sydney College
Clinical Trials
- Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin Start of enrollment: 2008 Dec 01
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
- Clinical Trial for Evaluation of Vermillion's Blood Test to Predict the Probability of Peripheral Artery Disease Start of enrollment: 2011 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 59 citationsMetanx in Type 2 Diabetes with Peripheral Neuropathy: A Randomized TrialVivian Fonseca, Lawrence A. Lavery, Tina K. Thethi, Yahya Daoud, Cyrus V. Desouza
The American Journal of Medicine. 2013-02-01 - 20 citationsClinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline...Robert R. Henry, Julio Rosenstock, Douglas S. Denham, Prakash Prabhakar, Lise Kjems
Diabetes Care. 2018-03-01 - 25 citationsGlucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.Jeremy Pettus, Schafer C Boeder, Mark P Christiansen, Douglas S Denham, Timothy S Bailey
Nature Medicine. 2022-10-01
Press Mentions
San Antonio Researchers Conducting Trial for Potential COVID-19 Nasal Spray VaccinationMay 6th, 2021
Clinical Trials of Texas Conducts Clinical Trial of Implantable Device for Type 1 DiabetesSeptember 15th, 2019- San Antonio’s Clinical Trials of Texas Enrolls Patients for a Pneumonia Vaccine Clinical TrialJuly 16th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
